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Abstract
Background: Interleukin-32 (IL-32) is a newly described cytokine produced after stimulation by IL-2 or IL-18 and IFN-c. IL-32
has the typical properties of a pro-inflammatory mediator and although its role in rheumatoid arthritis has been recently
reported its effect on the osteoclastogenesis process remains unclear.
Methodology/Principal Findings: In the present study, we have shown that IL-32 was a potent modulator of
osteoclastogenesis in vitro, whereby it promoted the differentiation of osteoclast precursors into TRAcP+ VNR+
multinucleated cells expressing specific osteoclast markers (up-regulation of NFATc1, OSCAR, Cathepsin K), but it was
incapable of inducing the maturation of these multinucleated cells into bone-resorbing cells. The lack of bone resorption in
IL-32-treated cultures could in part be explain by the lack of F-actin ring formation by the multinucleated cells generated.
Moreover, when IL-32 was added to PBMC cultures maintained with soluble RANKL, although the number of newly
generated osteoclast was increased, a significant decrease of the percentage of lacunar resorption was evident suggesting a
possible inhibitory effect of this cytokine on osteoclast activation. To determine the mechanism by which IL-32 induces such
response, we sought to determine the intracellular pathways activated and the release of soluble mediators in response to
IL-32. Our results indicated that compared to RANKL, IL-32 induced a massive activation of ERK1/2 and Akt. Moreover, IL-32
was also capable of stimulating the release of IL-4 and IFN-c, two known inhibitors of osteoclast formation and activation.
Conclusions/Significance: This is the first in vitro report on the complex role of IL-32 on osteoclast precursors. Further
clarification on the exact role of IL-32 in vivo is required prior to the development of any potential therapeutic approach.
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Introduction
Interleukin-32 (IL-32) is a newly described cytokine produced
mainly by T-, natural killer, epithelial cells and monocytes after
stimulation by Interleukin-2, Interleukin-18 or IFN-c [1,2]. It was
formerly known as natural killer cell transcript 4 [3]. Although IL-
32 can bind proteinase 3, a neutrophil-derived serine protease, its
receptor is unknown [4,5]. IL-32 has the typical properties of a
pro-inflammatory mediator by stimulating TNF-a, IL-1b and IL-8
production and by activating the NF-kB and p38 mitogen-
activated protein (MAP) kinase pathways [1]. IL-32 seems to be
involved in a variety of diseases such as inflammatory bowel
disease, myelodysplastic syndrome and chronic myelomonocytic
leukaemia, HIV infection [6–8]. Moreover, it has been reported
recently that in a cohort of patient suffering with rheumatoid
arthritis, IL-32 was significantly increased in the synovial tissue
and that its levels were strongly correlated with the severity of the
disease [9,10]. Moreover, IL-32 has been demonstrated to induce
joint inflammation with concomitant mild cartilage damage when
injected intra-articularly in murine knee joints [9]. Despite these
observations, the impact of this cytokine on osteoclastogenesis
remains unclear.
Osteoclasts are multinucleated cells originating from the
hematopoietic lineage (CFU-GM) that specifically function in
lacunar bone resorption [11,12]. Osteoclast differentiation from
circulating hematopoietic precursors requires the presence of
macrophage colony-stimulating factor (M-CSF) and the receptor
activator for nuclear factor kB ligand – RANKL [13–16].
RANKL is a member of the tumor necrosis factor (TNF)
superfamily that is expressed on osteoblasts and T-cells and
interacts with its receptor, RANK, expressed on osteoclast
precursors [15,17–19]. It has been reported that the interaction
of RANK with RANKL results in the activation of distinct
intracellular pathways: NFATc1, NF-kB, Akt, and MAP kinase
pathways. Osteoprotegerin (OPG) acts as a decoy receptor for
RANKL and blocks RANKL-mediated osteoclast differentiation
and stimulation of osteoclast resorbing activity [20,21]. Although
RANKL is a crucial factor for osteoclastogenesis, RANKL-
independent mechanisms have been evidenced with several pro-
inflammatory cytokines such as TNF-a, LIGHT and IL-8 [22–
25].
The aim of the present study was to investigate the role of IL-32
on the differentiation and maturation of human osteoclast
precursors. Our findings suggested that although IL-32 induced
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VNR+ cells expressing OSCAR and Cathepsin K and induced
the activation of NFATc1, NF-kB, ERK1/2 and JNK, it was
incapable of modulating Akt activation in a level similar to
RANKL. Morphologically multinucleated cells generated in
response to IL-32 did not form F-actin on dentine slices and
ultimately were unable to resorb bone in vitro.
Results
IL-32 induces the differentiation of adherent PBMCs into
multinucleated TRAcP+,V N R + cells in the absence of
sRANKL
After 14 days in culture, the presence of newly-formed
multinucleated cells were detected in response to IL-32. To
determine the optimal concentration of IL-32 required to
differentiate PBMCs into multinucleated cells in vitro, a dose
response experiment was performed. IL-32 was capable of
inducing the formation of multinucleated TRAcP and VNR
positive cells as shown in Figure 1A. The number of TRAcP
positive multinucleated cells was increased by a significant 4.5-fold
at the lowest concentration studied (25 ng/ml) compared to M-
CSF alone (361612 vs. 7965; p,0.0001) as seen on Figure 1B.
The dose dependent effect of IL-32 was statistically significant and
clearly evident as illustrated in Figure 1B. A similar pattern for the
number of VNR positive multinucleated cells in response to IL-32
was noted (data not shown).
The size of newly-formed multinucleated TRAcP+ VNR+ cells
in response to IL-32 was also significantly greater than in M-CSF-
treated culture (Fig. 1C). Interestingly, at doses higher than 50 ng/
ml, IL-32 did not markedly influence the size of the newly-formed
multinucleated TRAcP+ VNR+ cells. The number of nuclei per
multinucleated cells was significantly increased in IL-32-treated
cultures compared to M-CSF alone with a 2-fold increase for the
lowest concentration of 25 ng/ml (9.4462.74 vs. 4.6661.36;
p,0.0001). The dose dependent effect of IL-32 was clearly evident
as illustrated in Figure 1D. Based on the data obtained in
Figures 1B–1D, the optimal dose for any subsequent experiments
was chosen to be 100 ng/ml.
IL-32 is capable of inducing the formation of
multinucleated cells exhibiting specific osteoclast
markers
After 3 days of treatment with M-CSF/IL-32 or M-CSF/
RANKL (as a positive control), the expression of specific osteoclast
markers such as NFATc1, TRAF6, OSCAR and Cathepsin K,
Figure 1. IL-32-treatment induced a dose dependent differentiation of osteoclast precursors. (A) TRAcP and VNR positive staining of
newly-formed multinucleated cells differentiated from human PBMCs in the presence of 25 ng/ml of M-CSF6100 ng/ml of IL-32. Black bar represents
50 mm. (B) The number of newly-generated TRAcP positive multinucleated cells is dependent on the concentration of IL-32. (C) Size of newly-
generated multinucleated cells is not increased at doses higher than 50 ng/ml of IL-32. (D) The number of nuclei per newly-generated
multinucleated cells is significantly increased in a dose-dependent manner with the optimal response at 100 ng/ml of IL-32. P values represent the
statistical significances between each group using Mann-Whitney test.
doi:10.1371/journal.pone.0004173.g001
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(Fig. 2A). The number of newly-generated multinucleated cells
formed in the presence of IL-32 was statistically lower than those
formed in response to sRANKL (645637 vs. 555618; p=0.032)
(Fig. 2B). In contrast, the size and the number of nuclei of the
newly-formed multinucleated cells in response to IL-32 were
significantly increased by 1.4-fold and 2.3-fold respectively
compared to those generated in the presence of sRANKL
(14666.4 mm vs. 10263.4 mm; p,0.0001 and 18.862.5 vs.
8.261.3; p,0.0001) (Fig. 2C and 2D).
When a combination of IL-32 and sRANKL (both at 100 ng/
ml) were added to the osteoclast precursors, the number of newly-
formed osteoclasts was increased by 2.2-fold compared to
sRANKL-treated cultures (1417651 vs. 645637; p,0.0001)
(Fig. 2B). Paradoxically, the size of the newly-formed osteoclasts
in response to IL-32 and sRANKL was significantly reduced
compared to IL-32-treated cultures (9663 mm vs. 14666.4 mm;
p,0.0001). However, compared to sRANKL-treated cultures, the
size of TRAcP positive multinucleated osteoclasts were not
significantly different as those formed in the presence of IL-32
and sRANKL (9663 mm vs. 10263.4 mm; p=0.310) (Fig. 2C).
The number of nuclei per newly-formed osteoclast was signifi-
cantly reduced in PBMC cultures treated with combined
sRANKL/IL-32 as compared to IL-32 alone (1161.1 vs.
18.862.5; p,0.0001) (Fig. 2D).
Signalling pathways involved in response to IL-32 and
compared with RANKL
In order to better characterize the multinucleated cells formed
in response to IL-32, we investigated, using Western blot analysis,
the activation of downstream signalling pathways. After 15 min-
utes of treatment with M-CSF or RANKL or IL-32, the activation
of several intracellular pathways known to be activated by
RANKL, were determined. In response to IL-32 or RANKL,
PBMCs underwent a rapid activation of JNK and NF-kBa s
Figure 2. Comparison of the effects of IL-32 and soluble RANKL on the differentiation and maturation of osteoclast precursors. (A)
IL-32 was capable of inducing the expression of specific osteoclastic markers as illustrated. PBMCs were exposed to the factors for 72 h prior to
Western blot analysis. b-actin was used as an internal control for gel loading. (B) Number of newly formed osteoclasts. Although the number of
multinucleated cells formed in response to IL-32 was significantly increased compared to M-CSF-treated cultures, this parameter was significantly
decreased when compared with the soluble RANKL-treated cultures. The combined treatment of PBMCs with sRANKL/IL-32 resulted in a highly
significant increase in the number of newly formed osteoclasts as compared to either of those factors alone. (C) Size of newly generated osteoclasts.
IL-32 increased the size of multinucleated cells compared to sRANKL cultures but was unable to increase the size of the newly formed osteoclasts
when combined with sRANKL. (D) Number of nuclei per osteoclast. Compared to sRANKL-treated cultures, multinucleated cells formed in response to
IL-32 exhibited more nuclei per cell indicating that the process of cell fusion may have been facilitated. P values represent the statistical significances
between each group using Mann-Whitney test.
doi:10.1371/journal.pone.0004173.g002
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tion of ERK1/2 was markedly increased by 3.6-fold in response to
IL-32 compared with RANKL. Although M-CSF alone induced a
strong and rapid activation of Akt, the addition of RANKL was
incapable of activating Akt in a similar level, indicating a possible
down-regulation of Akt activation by RANKL when associated
with M-CSF (Fig. 3). Interestingly, Akt activation in IL-32
treatment increased considerably compared to RANKL exposure.
IL-32 alone cannot induce the maturation of the newly-
formed osteoclast into bone –resorbing osteoclasts
In order to determine whether IL-32 alone or in combination
with sRANKL have a direct effect on the maturation of
osteoclasts, the expression of F-actin ring by the newly-formed
multinucleated cells and the extent of lacunar resorption was
examined on dentine slices of PBMC cultures after 21 days.
Multinucleated cells generated in the presence of sRANKL or in
combination of sRANKL/IL-32 presented an F-actin ring at their
periphery as shown in Figure 4A. However, multinucleated cells
generated in response to IL-32 did not similarly express F-actin
ring (Fig. 4A). Furthermore, IL-32 alone was shown to have no
effect on the maturation of newly-formed osteoclast as indicated in
Figure 4B and 4C. However, although the mean percentage
surface area resorption in response to sRANKL alone was
43.369.8%, the addition of IL-32 in combination to sRANKL
did not increase the extent of lacunar resorption and surprisingly it
significantly reduced this parameter by 2.6-fold (Fig. 4C).
To ascertain the mechanism by which IL-32 induced the
observed decrease in the percentage lacunar resorption in
sRANKL-treated cultures, the size of the lacunar pits were
determined by image analysis. In cultures treated with IL-32 and
sRANKL the mean diameter of the pits was significantly reduced
by 1.4-fold compared to sRANKL alone (68.361.0 mm vs.
94.761.6 mm; p,0.0001) (Fig. 4D).
Multinucleated cells formed in response to IL-32 are not
solely mediated through the RANK/RANKL pathway
Figure 5 demonstrates the inhibitory effects of excess OPG on
sRANKL-mediated and IL-32-mediated osteoclastogenesis. OPG
at 250 ng/ml was capable of significantly inhibiting the number of
RANKL-inducing osteoclast formed by 6.2-fold as compared to
sRANKL alone (10465 vs. 645637; p,0.0001) (Fig. 5A). The
size of the osteoclast generated in the presence of sRANKL and
OPG was significantly reduced as compared to sRANKL alone
(7362.2 mm vs. 10263.4 mm; p,0.0001) (Fig. 5B) but the
number of nuclei per osteoclast was significantly increased
(Fig. 5C). Although the concentration of OPG employed was
unable to completely inhibit the number of osteoclasts formation
in RANKL-treated cultures, this dose was suitable in completely
abolishing the activity of the newly-formed osteoclasts in the
resorption assay (data not shown).
OPG treatment resulted in a moderate inhibition (1.3-fold) of
the newly-formed multinucleated cells in response to IL-32 as
compared to cultures where no exogenous OPG was added
(423622 vs. 555618; p=0.003, Fig. 4A). Moreover, OPG was
capable of reducing the size and the number of nuclei per newly-
formed multinucleated cells generated in response to IL-32
(10463.9 mm vs. 14666.4 mm; p,0.0001 and 11.662 vs.
18.862.5; p,0.0001, Fig. 5B). As the extent of lacunar resorption
did not mirror the number of multinucleated cells formed in
cultures treated with IL-32 (Fig. 4B), the addition of OPG to these
cultures did not affect the surface area resorption by IL-32 as there
was no evidence of pit formation in response to this cytokine (data
not shown).
OPG inhibits osteoclast formation and resorption in
sRANKL/IL-32 combined treatment
In cultures treated with IL-32 and sRANKL, the number of
multinucleated osteoclasts formed was markedly reduced in
response to excess concentration of OPG as compared to
untreated cultures (Fig. 6A). The size and the number of nuclei
of the newly-formed osteoclasts were, however, unaffected in
cultures treated with sRANKL, IL-32 and OPG as compared to
conditions in the absence of OPG (Fig. 6B and 6C). OPG
treatment of sRANKL/IL-32 PBMC cultures resulted in a
complete inhibition of lacunar resorption as shown in Figure 6D.
Release of soluble mediators in response to IL-32
Figure 7 illustrates the level of cytokines known to induce
osteoclastogenesis (Fig. 7A) and factors known to inhibit osteoclast
differentiation (Fig. 7B), released in the cell culture supernatant
after stimulation by 100 ng/ml of IL-32. After 24 hrs, the levels of
TNF-a, IL-6, LIGHT, MIP-1a, VEGF, IFN-c and IL-4 were
significantly higher compared to unstimulated cultures, where
Figure 3. Effects of IL-32 on signalling pathways involved during osteoclastogenesis. Phosphorylation of ERK1/2, JNK, Akt and IkB-a in
human PBMCs after 15 minutes exposure to RANKL or IL-32. b-actin was used an internal control of gel loading.
doi:10.1371/journal.pone.0004173.g003
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After 48 hrs, a similar pattern of cytokine release was evidenced
with the detection of high levels of TNF-a, IL-6, LIGHT, MIP-1a,
VEGF, IFN-c and IL-4. Here again in the unstimulated culture
none of these cytokines were evidenced. Soluble RANKL was
undetectable in the supernatant of IL-32-treated or unstimulated
cultures after 24 hrs and 48 hrs.
Discussion
Osteoclasts are multinucleated cells responsible for bone
resorption and are derived from hematopoietic precursor cells
that circulate in the blood [26–28]. It is currently thought that two
critical factors supplied by osteoblasts, M-CSF and RANKL, are
essential for the differentiation and maturation of osteoclast
precursors [11,29]. Although M-CSF defective mice (op/op) show
an osteopetrotic phenotype, it can spontaneously reverse with age,
suggesting that alternative osteoclastic pathways do exist [30–32].
Hepatocyte growth factor (HGF), vascular endothelial growth
factor (VEGF) and Flt3 ligand have all been shown to support
osteoclast formation in the absence of M-CSF [33–35]. Further-
more mice deficient in either RANKL or its receptor RANK also
show an osteopetrotic phenotype that is caused by the complete
lack of osteoclast in their bones [36,37]. Although no osteoclasts
can be identified in the bone of RANKL or RANK deficient mice,
this may not be simply because of the complete failure of
osteoclastogenesis. Indeed, RANKL is a survival factor for
differentiated osteoclasts [38] and it is plausible that impaired
osteoclast differentiation superimposed on a shortened lifespan
might also explain the observed phenotype in RANKL or RANK
deficient mice [39]. As such, alternative RANKL-independent
pathways (e.g. LIGHT, TGFb and TNF-a) have been reported to
support osteoclastogenesis in the presence of excess osteoprote-
gerin, an inhibitor of RANKL-RANK interactions [23,24,40].
The emergence of the osteoimmunology field has demonstrated
that activated T cells directly modulate osteoclastogenesis and
bone resorption [41,42], and that T cell products, such as IL-17,
TWEAK, GM-CSF and IFN-c, can regulate osteoclast formation
[43–45]. The present study sought to determine the role of IL-32,
a newly described cytokine presenting characteristic of pro-
inflammatory cytokine and involved in a variety of inflammatory
disorders [1,6–10] in osteoclast differentiation and activation. We
have demonstrated that multinucleated cells formed in response to
IL-32 expressed several specific markers of osteoclast such as
activation of the NF-kB and MAP kinase pathways, expression of
TRAcP and VNR, up-regulation of NFATc1, OSCAR and
Cathepsin K which were also observed in RANKL-treated
cultures. However, IL-32-treated multinucleated cells were unable
to induce bone resorption in vitro. One explanation for the lack of
bone resorption could be attributed to the failure of the
multinucleated cells generated in response to IL-32 to express F-
actin ring which ultimately is required for anchorage of the cells
prior to bone resorption.
An important step in the process of osteoclast differentiation is
the induction of NFATc1 above a critical threshold [39]. This is
Figure 4. IL-32 was unable to induce the maturation of osteoclasts in vitro. (A) F-actin staining of multinucleated cells cultured with M-CSF
and sRANKL, M-CSF and IL-32 and M-CSF, sRANKL and IL-32. White bar represents 80 mm. IL-32-treated cultures did not exhibit evidence of F-actin
ring formation indicating the lack of anchorage of osteoclasts on dentine surface. (B) Evidence of lacunar resorption on dentine slices cultured with
M-CSF and sRANKL, M-CSF and IL-32 and M-CSF, sRANKL and IL-32. Black bar represents 250 mm. Multinucleated cells formed in response to IL-32
were incapable of lacunar resorption. (C) Treatment of PBMCs with M-CSF and IL-32 failed to induce the maturation of newly-formed osteoclasts as
evident by the lack of lacunar resorption on dentine slices. However, sRANKL-treatment of PBMCs resulted in a 43.369.8% percentage area
resorption. Combined treatment of sRANKL and IL-32 resulted in a significant decrease of 2.6 fold in percentage area resorption compared to sRANKL
alone. (D) The mean diameter of the lacunar pits formed in response to sRANKL and IL-32 treatment was significantly decreased compared to those
generated in response to sRANKL alone. P values represent the statistical significances between each group using Mann-Whitney test.
doi:10.1371/journal.pone.0004173.g004
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sufficient to induce osteoclast differentiation [46]. In the present
study, IL-32 was capable of up-regulating the expression of
NFATc1 compared to M-CSF-treated cultures or even M-CSF/
RANKL-treated cultures. Moreover, in response to IL-32, these
cells expressed high levels of OSCAR and Cathepsin K, two
markers that are specific for osteoclasts [47,48]. According to the
different markers expressed by the cells in response to IL-32, it is
reasonable to conclude that these multinucleated cells are likely to
be ‘‘immature osteoclasts’’. Recently, Kim et al. [39] have
reported that TNF-a is capable of inducing multinucleation of
osteoclast precursors and expression of osteoclast phenotypic
markers (TRAcP, F-actin) in RANK-deficient cells, but was unable
to induce evidence of lacunar bone resorption. In the present
study, although PBMCs released pro-osteoclastic mediators (TNF-
a, IL-6, LIGHT, MIP-1a and VEGF), the lack of lacunar
resorption in IL-32-treated cultures could be explained by the fact
that IL-32 stimulated the release of known osteoclastic inhibitors,
i.e. IL-4 and IFN-c. Our results herein indeed indicated that this is
the case as we demonstrated a significant increase in the release of
IL-4 and IFN-c from IL-32-stimulated PBMCs as compared to
unstimulated cells.
Tumour necrosis factor receptor-associated factor 6 (TRAF6)
has been reported to be important for osteoclast activation, i.e.
lacunar bone resorption [49]. The complex role of IFN-c in
osteoclastogenesis has been previously addressed by Takayanagi et
al. [50]. They have shown that IFN-c induces rapid degradation of
TRAF6, which results in strong inhibition of the RANKL-induced
activation. We therefore speculated that the inhibitory effects of
IL-32 alone or in combination with soluble RANKL could partly
be attributed to TRAF-6 degradation. However, surprisingly, we
found that TRAF6 is not degraded but it is overexpressed in
response to IL-32 treatment compared to RANKL. Recently, Gao
et al. have shown that IFN-c exhibits a ‘‘direct’’ anti-resorptive
effect by blunting osteoclast differentiation. However, IFN-c can
act ‘‘indirectly’’ as a pro-resorptive factor by stimulating T-cells to
express RANKL and TNF-a [51]. In the present study, we used
PBMCs as a source of osteoclast precursors and although cells
were washed thoroughly to eliminate non-adherent cells (mainly
B- and T-cells), it is plausible that some T-cells could have been
present in the culture and contributed to osteoclastogenesis. This
hypothesis is also reinforced by the evidence that the addition of
excess OPG to the IL-32-treated cultures led to a marked decrease
in the number and size of newly-formed multinucleated cells.
Although we were unable to detect any soluble RANKL in the
supernatant of IL-32-treated cultures, it is conceivable to suggest
that effects of IL-32 could have been partially mediated through a
RANKL-dependent mechanism. We have previously observed
Figure 5. Effect of OPG treatment on sRANKL- and IL-32-mediated osteoclastogenesis. (A) Number of newly-generated osteoclasts in the
presence of OPG. OPG significantly decreased the number of osteoclasts generated with sRANKL but OPG inhibition had only a partial effect in PBMC
cultures treated with IL-32. (B) Size of the newly-generated osteoclasts. OPG treatment resulted in a decrease in the size of the newly-formed
osteoclasts generated with sRANKL and/or IL-32. (C) Number of nuclei per osteoclast. OPG treatment significantly increased the number of nuclei per
osteoclast in sRANKL-treated cultures and markedly abrogated this parameter in IL-32-treated cultures. P values represent the statistical significances
between each group using Mann-Whitney test.
doi:10.1371/journal.pone.0004173.g005
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in T-cell cultures (unpublished data) and it is likely that a few
numbers of RANKL-expressing T-cells may have been present in
the PBMC cultures. As IL-32 is known to be produced by PBMCs
in response to IFN-c [52], the effects of IFN-c in combination with
IL-32 on T-cells could have contributed to the inhibitory effects of
OPG observed herein.
The downstream signalling of RANK/RANKL interactions has
been extensively studied in the last decade. It has been shown that
the binding of RANKL to its receptor activated NF-kB, MAP
kinase and Akt pathways. However, downstream pathways
involved in response to IL-32 in osteoclasts are not fully elucidated.
In our study, we found that PBMCs treatments with M-CSF/IL-
32 or M-CSF/RANKL dramatically increased the activation of
NF-kB and JNK pathways compared to M-CSF-treated cultures.
However, the activation of the Akt pathways appeared more
complicated. M-CSF or M-CSF/IL-32 treatments were capable of
strongly activating Akt pathways compared to M-CSF/RANKL.
These results appeared controversial with the consensus that
RANKL activates Akt [11,53]. However, most of the studies
showing Akt activation in response to RANKL have been done in
in vitro models of bone marrow co-cultures or using murine cell
line, RAW264.7 cells. In these studies, treatment of serum-starved
osteoclast precursors with soluble RANKL resulted in a significant
activation of the Akt pathway as compared to cultures in the
absence of RANKL. This is in conflict with the present findings
whereby after exposure of M-CSF–treated PBMCs to sRANKL,
Akt activation was down-regulated compared with M-CSF alone.
Interestingly, M-CSF/IL-32 treatment of PBMCs resulted in a
similar level of Akt activation compared to M-CSF treatment. It
has also been extensively shown that M-CSF, via its receptor c-
fms, is a strong activator of PI-3 Kinase which in turn activates Akt
[54,55]. In the present study, we demonstrated that M-CSF/IL-32
treatment exhibited levels of Akt activation similar to M-CSF
treatment and it is questionable whether Akt activation in response
to IL-32 or RANKL results in the same downstream effectors
(Fig. 8).
We have also evidence of a marked increase in the
phosphorylation of ERK1/2 in M-CSF/IL-32 compared to M-
CSF/RANKL treated cultures. It is well known that activated
ERK1/2 translocates to the nucleus and activates its target to
promote the expression of specific genes (reviewed in [56]). It
Figure 6. Effects of OPG on IL-32/sRANKL-mediated osteoclastogenesis. (A) The number of multinucleated TRAcP positive cells formed in
response to IL-32/sRANKL treatment was significantly reduced in the presence of excess OPG. (B) The size of the newly-formed TRAcP positive
multinucleated cells was unaffected by the presence of OPG in IL-32/sRANKL-treated cultures. (C) The number of nuclei noted in TRAcP positive cells
formed in response to IL-32/sRANKL treatment was not affected by the OPG treatment. (D) The percentage area lacunar resorption was completely
abolished when PBMCs were treated with IL-32/sRANKL and excess OPG. P values represent the statistical significances between each group using
Mann-Whitney test.
doi:10.1371/journal.pone.0004173.g006
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ERK1/2 in M-CSF/IL-32 are different to those known for M-
CSF/RANKL (Fig. 8). This is also reinforced by the morpholog-
ical differences (e.g. differences in cell size and number of nuclei,
lack of F-actin ring) observed in the multinucleated cells generated
in presence of IL-32 or RANKL.
Our current findings suggest that IL-32 was capable of inducing
osteoclast differentiation in a manner partially independent of the
RANK/RANKL pathway. However, although IL-32 could
increase the release of pro-inflammatory mediators known to
positively influence osteoclastogenesis, it was unable to induce the
activation of these newly-formed multinucleated cells into bone-
resorbing osteoclasts and had a direct inhibitory effect on
osteoclast activation in vitro. It is worth noting that IL-32 has
direct effects on other cell types such as epithelial cells, T-cells,
natural killer cells and monocytes. Although the present study only
addressed its direct role on osteoclast precursors, IL-32 could also
indirectly modulate osteoclastogenesis in vivo. The complex role of
IL-32 in the patho-physiology of bone disorder therefore requires
further clarification prior to the development of any potential
therapeutic approach.
Materials and Methods
Recombinant IL-32a, M-CSF and OPG were purchased from
R&D systems Europe (Abingdon, UK) and soluble RANKL was
purchased from PeproTech (London, UK). Recombinant cyto-
kines were aliquoted and stored at 280uC on day of purchase. All
chemicals for immuno-histochemical staining were purchased
from Sigma-Aldrich (Poole, UK).
Preparation and culture of human peripheral blood
mononuclear cells (PBMCs)
The study was approved by the Oxfordshire Research Ethics
Committee (CO1-071). PBMCs were isolated from 6 normal
healthy volunteers as previously described [57]. Briefly, donors
were free of prescribed and over the counter prescription.
Antecubital venous blood was supplied by National Blood Service
(UK). Blood was diluted 1:1 in a-minimal essential medium
(MEM) (Invitrogen, Paisley, UK), layered over Histopaque
(Sigma-Aldrich Chemicals, Poole, UK), and centrifuged (6936g)
for 20 min. The interface layer was resuspended in MEM then
centrifuged (6006g) for a further 10 min after which the resultant
Figure 7. Release of soluble mediators in response to treatment of PBMCs with IL-32 after 24 hrs and 48 hrs. (A) The stimulation of
PBMCs with 100 ng/ml of IL-32 induced the release of TNF-a, IL-6, LIGHT, MIP-1a, VEGF. RANKL was undetectable in the supernatant. (B) Levels of
IFN-c and IL-4. The minimum dose detectable was 1.6 pg/ml for TNF-a, 0.70 pg/ml for IL-6, 5.5 pg/ml for LIGHT, 10 pg/ml for MIP-1a, 5 pg/ml for
VEGF, 5 pg/ml for RANKL, 8.0 pg/ml for IFN-c and 10 pg/ml for IL-4. Unstimulated PBMCs were unable to release any of these soluble mediators.
doi:10.1371/journal.pone.0004173.g007
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inactivated fetal calf serum (FCS, Invitrogen, Paisley, UK) and
counted in a haemocytometer following lysis of red blood cells by a
5% (v/v) acetic acid solution.
Assessment of osteoclast formation
To assess the extent of osteoclast formation and activation,
isolated human PBMCs from whole blood were cultured on glass
coverslips and dentine slices as described previously [57]. Briefly,
5610
5 PBMCs were added to 4 mm diameter dentine slices and
6 mm diameter glass coverslips in MEM containing 100 UI/ml
penicillin, 100 mg/ml streptomycin and 10% FCS. After 2 h
incubation, cultures were vigorously rinsed in medium to remove
non-adherent cells, and then maintained in 1 ml MEM/FCS with
25 ng/ml recombinant human M-CSF with or without 100 ng/ml
recombinant human sRANKL for up to 21 days. To assess
whether IL-32 could influence osteoclastogenesis, PBMCs were
cultured in the following conditions:
(i) 25 ng/ml of M-CSF (negative control)
(ii) M-CSF (25 ng/ml) and sRANKL (100 ng/ml) as a positive
control (sRANKL added on day7)
(iii) M-CSF (25 ng/ml) and various concentration of IL-32
(25 ng/ml, 50 ng/ml, 100 ng/ml and 200 ng/ml) (IL-32
added on day7)
(iv) M-CSF (25 ng/ml), 100 ng/ml sRANKL and 100 ng/ml
IL-32 (the latter two added on day7)
(v) M-CSF (25 ng/ml), sRANKL (100 ng/ml) and 250 ng/ml
OPG, a dose known to completely block the sRANKL-
mediated bone resorption [58] (both sRANKL and OPG
added at day7).
(vi) M-CSF (25 ng/ml), 100 ng/ml IL32-a and 250 ng/ml
OPG to determine the possible involvement of the
sRANKL pathway (IL-32 and OPG added on day7).
(vii) M-CSF (25 ng/ml), 100 ng/ml IL-32, 100 ng/ml
sRANKL and 250 ng/ml OPG (IL-32, sRANKL and
OPG added at day7).
All factors were replenished every 2–3 days and the cultures
were maintained for up to 21 days.
Characterization of newly-formed osteoclast on glass
coverslips and dentine slices
Tartrate resistant acid phosphatase (TRAcP). After
14 days in culture, the expression of TRAcP (one of the known
osteoclastic markers [59]) on the adherent cells on the coverslips
were examined histochemically, as described previously [59].
Briefly, coverslips were removed from the culture wells and rinsed
promptly in PBS buffer, fixed with formalin (10% in PBS buffer)
for 10 minutes and rinsed in distilled water. TRAcP was
histochemically revealed by a simultaneous coupling reaction
using Naphtol AS-BI-phosphate as substrate and Fast violet B as
the diazonium salt. The coverslips were then incubated for
90 minutes at 37uC in the dark, rinsed three times in distilled
Figure 8. Schematic representation of downstream pathways activated by RANKL or IL-32 treatment. The discrepancy observed
between IL-32 and RANKL signalling pathways (i.e. increased ERK1/2 and Akt activation by IL-32) may lead to the activation of different downstream
targets which in turn could contribute to the inability of cells to express F-actin ring and resorb in response to IL-32.
doi:10.1371/journal.pone.0004173.g008
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30 minutes. Coverslips were then rinsed in distilled water,
counterstained with DAPI for 20 minutes and allowed to dry
before mounting using an aqueous medium. TRAcP positive cells,
with more than three nuclei, were considered as osteoclasts. The
number of newly generated osteoclasts and the number of nuclei
per osteoclast (after counterstaining with DAPI) were assessed
using light microscopic examination. The size of the osteoclasts
was determined by image analysis using the ImageJ Freeware
(NIH, Bethesda, MD).
Vitronectin receptor (VNR). Adherent cells on coverslips
were fixed with 4% paraformaldehyde after 14 days of culture
and stained immuno-histochemically by an indirect
immunoperoxidase technique. This technique utilized the
monoclonal antibody 23C6 (Serotec, Oxford, UK), which is
directed against the VNR, CD51, an osteoclast-associated antigen
[60].
F-actin. Adherent cells on dentine slices were fixed in 4%
paraformaldehyde after 21 days of culture, washed in PBS and
stained histo-chemically with phalloidin-TRITC (500 ng/ml) for
45 minutes. Dentines slices were washed thoroughly in PBS prior
to mounting using 70:30 (v/v) water:glycerol and examined with
an Olympus BX40.
Lacunar resorption. After 21 days in culture, the dentine
slices were removed from the culture wells, placed in NH4OH (1N)
for 30 minutes and sonicated for 5 minutes to remove any
adherent cells. After rinsing in distilled water, the dentine slices
were stained with 0.5% (v/v) toluidine blue (pH 5.0) prior to
examination by light microscopy. The surface of each dentine slice
was examined for the presence of lacunar resorption and the
extent of eroded surface on dentine slices was determined using
image analysis on each dentine and data was expressed as the
percentage of surface area resorbed.
Western blot analysis
PBMCs were cultured on 25 cm
2 flasks with M-CSF (25 ng/ml)
alone or M-CSF and soluble RANKL (100 ng/ml) or M-CSF and
IL-32 (100 ng/ml) for the indicated period of time. Cells were
washed in cold PBS and homogenised in lysis buffer containing
50 mM Tris-Hcl pH 7, 100 mM NaCl, 50 mM NaF, 3 mM
Na3VO4, protease inhibitor cocktail (Sigma-Aldrich) and 1%
Nonidet P-40. Samples were spun at 13,000 rpm for 30 min at
4uC, the supernatant was collected and protein concentration was
determined using a BCA protein assay kit (Pierce Biotechnology,
Rockford, IL). Samples (20–50 mg per lane) were run on a 10%
acrylamide and blotted onto a PVDF membrane. The membranes
were washed in Tris buffered saline (TBS) and blocked with 5%
bovine serum albumin. Samples were incubated overnight with
one of the following specific antibodies for IkBa, Phospho-IkBa,
ERK1/2, Phospho-ERK1/2, JNK, Phospho-JNK, Akt, Phospho-
Akt, TRAF6 (Cell Signalling), Cathepsin K, NFATc1, OSCAR
(Santa Cruz Biotechnology) and b-actin (Sigma-Aldrich). Subse-
quently the membranes were washed in TBS and incubated with
the appropriate secondary antibodies coupled to HRP. Immuno-
reactive bands were visualised using an ECL kit (Amersham, UK).
The degree to which the different markers were induced was
determined by normalizing the specific signal to that of actin using
ImageJ Freeware (NIH).
Cytokine release in response to IL-32
In order to determine the extent of different cytokine release
involved in the osteoclastogenic process, the condition media of
2610
6 PBMCs exposed to 100 ng/ml of IL-32, a concentration
that was shown to influence osteoclastogenesis (see above), was
collected after eight and nine days in culture (i.e. after one and two
days of presence with IL-32). These time points were chosen in
order to determine whether IL-32 is capable of inducing the
release of other known osteoclastogenic markers (listed below)
directly from PBMCs already stimulated by M-CSF. The
conditioned media was thereafter collected, centrifuged at 8006
g for 30 min, aliquoted and frozen at 280uC prior to evaluation of
the levels of human IFN-c, IL-4, IL-6, LIGHT, MIP-1a also
known as CCl-3, TNF-a and VEGF (Human Quantikine Kits,
R&D Systems Europe, Abingdon, UK) according to the
manufacturer protocol. According to the manufacturer, the
minimum dose detectable (MDD) of these cytokines is 8.0 pg/ml
for IFN-c, 10 pg/ml for IL-4, 0.70 pg/ml for IL-6, 5.5 pg/ml for
LIGHT, 10 pg/ml for MIP-1a, 1.6 pg/ml for TNF-a and 5 pg/
ml for VEGF. Levels of soluble RANKL were detected using in-
house kit by coating a 96-well plate with recombinant human
OPG (R&D Systems Europe) and using a goat anti-human
RANKL (R&D Systems Europe) as a detection antibody. The
specificity of the kit was validated using recombinant soluble
RANKL from PeproTech (range from 0 to 1280 pg/ml). The
minimum dose detectable of RANKL is 5 pg/ml.
Statistical analysis
All experiments were repeated at least 6 times and the results
were expressed as mean6standard error of the mean. Non-
parametric Mann-Whitney test was used to compare the
differences between the groups using the SPSS statistical software
release 14.0. (SPSS inc. Chicago, IL). Differences at p,0.05 were
considered significant.
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